SCHEMBL863069

SCHEMBL863069

CC(=O)Nc1ccc(F)c(F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.58
NPC1 O15118 3/20 0.58
TSHR P16473 2/20 0.56
HPGD P15428 1/20 0.56
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
MAPT P10636 3/20 0.54
ALDH1A1 P00352 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
HTT P42858 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
HDAC1 Q13547 2/20 0.53
TDP1 Q9NUW8 1/20 0.52
CA12 O43570 1/20 0.52
BRD4 O60885 1/20 0.52
NR1I2 O75469 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
MB P02144 1/20 0.52
CYP1A1 P04798 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30368269 1.00 RAB9A (0.58) RAB9ANPC1TSHRHPGDMEN1
SCHEMBL30675577 0.84 PKM (0.59) RAB9ANPC1TSHRMEN1KMT2A
SCHEMBL13414534 0.84 ALDH1A1 (0.53) RAB9ANPC1TSHRMEN1KMT2A
SCHEMBL405478 0.84 ALDH1A1 (0.57) RAB9ANPC1TSHRMEN1KMT2A
SCHEMBL11802375 0.84 PKM (0.59) RAB9ANPC1TSHRMEN1KMT2A
SCHEMBL30421453 0.84 NPC1 (0.62) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL8251619 0.84 NPC1 (0.62) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL9234372 0.84 SMN1; SMN2 (0.60) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL1136776 0.84 PKM (0.54) RAB9ANPC1TSHRMEN1KMT2A
SCHEMBL147440 0.82 IDO1 (0.65) RAB9ANPC1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651643-A4 BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS IRM LLC (BM) 2008-10-08 EP claimed
US-20070259852-A1 BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS IRM LLC 2007-11-08 US claimed
US-7253164-B2 Bicyclic compounds and compositions as PDF inhibitors IRM LLC (BM) 2007-08-07 US claimed
EP-1651643-A2 BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS IRM, LLC (BM) 2006-05-03 EP claimed
US-20050197326-A1 Bicyclic compounds and compostions as PDF inhibitors IRM LLC 2005-09-08 US claimed
WO-2005011611-A2 BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS IRM, LLC (BM) 2005-02-10 WO claimed
WO-2025090871-A1 ELECTROPHILIC PURINE COMPOUNDS FOR MODIFICATION OF PROTEINS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2025-05-01 WO disclosed
EP-3356345-B1 HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS MAX PLANCK GESELLSCHAFT (DE) 2023-11-08 EP disclosed
EP-3466946-B1 THIOPHENE, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL APPLICATION OF SAME DONGBAO PURPLE STAR HANGZHOU BIOPHARMACEUTICAL CO LTD (CN) 2023-08-30 EP disclosed
WO-2023158862-A2 STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC. (US) 2023-08-24 WO disclosed
EP-3837732-A1 NOVEL CATALYTIC MATERIALS University of Tartu (EE) 2021-06-23 EP disclosed
US-10829483-B2 Thiophene, manufacturing method thereof, and pharmaceutical application of same CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD. (CN) 2020-11-10 US disclosed
US-20200140423-A1 Thiophene, Manufacturing Method Thereof, And Pharmaceutical Application Of Same DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD (CN) 2020-05-07 US disclosed
EP-0230946-A2 Process for the preparation of quinolonecarboxylic acid derivatives KYORIN PHARMACEUTICAL CO., LTD. (JP) 1987-08-05 EP disclosed
EP-0230947-A1 Halogenobenzoic acid derivatives and their preparation KYORIN PHARMACEUTICAL CO., LTD. (JP) 1987-08-05 EP disclosed
EP-0230948-A2 Benzoylacetic acid ester derivatives and process for their preparation KYORIN PHARMACEUTICAL CO., LTD. (JP) 1987-08-05 EP disclosed
EP-0029658-A1 Salts of dihalo-2-quinoxaline carboxylic acids, their preparation and pharmaceutical formulations containing them ELI LILLY AND COMPANY (US) 1981-06-03 EP disclosed
US-4264600-A VIRICIDES ELI LILLY AND COMPANY (US) 1981-04-28 US disclosed
US-4252954-A VIRICIDES ELI LILLY AND COMPANY (US) 1981-02-24 US disclosed
EP-0010426-A1 Pharmaceutical composition containing 3,4-dihydro-3-oxo-2-quinoxalines, novel such quinoxalines and processes for the production thereof ELI LILLY AND COMPANY (US) 1980-04-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197326-A1 Bicyclic compounds and compostions as PDF inhibitors PDF, FDPS, DCTPP1 RAB9A 2389/4885NPC1 1383/4885TSHR 4619/4885
US-10829483-B2 Thiophene, manufacturing method thereof, and pharmaceutical application of same SLC10A6, TPMT, SLC6A6 RAB9A 2246/4885NPC1 248/4885TSHR 1127/4885
US-20200140423-A1 Thiophene, Manufacturing Method Thereof, And Pharmaceutical Application Of Same SLC10A6, TPMT, SLC6A6 RAB9A 2246/4885NPC1 248/4885TSHR 1127/4885
US-20070259852-A1 BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS PDF, FDPS, DCTPP1 RAB9A 1674/4885NPC1 761/4885TSHR 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.